BIOMAT Database Logo BIOMAT Database Logo

[Clinical experience in the use of bupivacaine as an anti-arrhythmia agent]. 1973

H Sakio, and Y Yoshida, and K Shimamura

UI MeSH Term Description Entries
D008012 Lidocaine A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE. Lignocaine,2-(Diethylamino)-N-(2,6-Dimethylphenyl)Acetamide,2-2EtN-2MePhAcN,Dalcaine,Lidocaine Carbonate,Lidocaine Carbonate (2:1),Lidocaine Hydrocarbonate,Lidocaine Hydrochloride,Lidocaine Monoacetate,Lidocaine Monohydrochloride,Lidocaine Monohydrochloride, Monohydrate,Lidocaine Sulfate (1:1),Octocaine,Xylesthesin,Xylocaine,Xylocitin,Xyloneural
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011342 Procainamide A class Ia antiarrhythmic drug that is structurally-related to PROCAINE. Procaine Amide,Apo-Procainamide,Biocoryl,Novocainamide,Novocamid,Procainamide Hydrochloride,Procamide,Procan,Procan SR,Procanbid,Pronestyl,Rhythmin,Amide, Procaine,Hydrochloride, Procainamide
D002045 Bupivacaine A widely used local anesthetic agent. 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide,Bupivacain Janapharm,Bupivacain-RPR,Bupivacaina Braun,Bupivacaine Anhydrous,Bupivacaine Carbonate,Bupivacaine Hydrochloride,Bupivacaine Monohydrochloride, Monohydrate,Buvacaina,Carbostesin,Dolanaest,Marcain,Marcaine,Sensorcaine,Svedocain Sin Vasoconstr,Bupivacain RPR
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001145 Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac

Related Publications

H Sakio, and Y Yoshida, and K Shimamura
[Use of lidoflazine (Clinium) as an anti-arrhythmia agent].
March 1979, Orvosi hetilap,
H Sakio, and Y Yoshida, and K Shimamura
[The use of lidoflazin (Clinium) as an anti-arrhythmia agent].
August 1976, Orvosi hetilap,
H Sakio, and Y Yoshida, and K Shimamura
[Adenosine as an anti-arrhythmia agent].
May 1995, Medizinische Monatsschrift fur Pharmazeuten,
H Sakio, and Y Yoshida, and K Shimamura
[Amiodarone as an anti-arrhythmia agent].
January 1985, Kardiologia polska,
H Sakio, and Y Yoshida, and K Shimamura
[Propafenone as an anti-arrhythmia agent].
November 1986, Wiadomosci lekarskie (Warsaw, Poland : 1960),
H Sakio, and Y Yoshida, and K Shimamura
[Lidocaine as an anti-arrhythmia agent].
July 1968, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
H Sakio, and Y Yoshida, and K Shimamura
[Lidocaine as an anti-arrhythmia agent].
June 1972, Die Medizinische Welt,
H Sakio, and Y Yoshida, and K Shimamura
[Adenosine as an anti-arrhythmia agent].
February 1996, Deutsche medizinische Wochenschrift (1946),
H Sakio, and Y Yoshida, and K Shimamura
[Clinical evaluation of amiodarone hydrochloride as an anti-arrhythmia agent].
January 1975, Revista de medicina de la Universidad de Navarra,
H Sakio, and Y Yoshida, and K Shimamura
[Lidocaine as an anti-arrhythmia agent. The pharmacological, experimental and clinical background for its use].
March 1969, Ugeskrift for laeger,
Copied contents to your clipboard!